Analysis of AI-Based Single-View 3D Reconstruction Methods for an Industrial Application

Machine learning (ML) is a key technology in smart manufacturing as it provides insights into complex processes without requiring deep domain expertise. This work deals with deep learning algorithms to determine a 3D reconstruction from a single 2D grayscale image. The potential of 3D reconstruction can be used for quality control because the height values contain relevant information that is not visible in 2D data. Instead of 3D scans, estimated depth maps based on a 2D input image can be used with the advantage of a simple setup and a short recording time. Determining a 3D reconstruction from a single input image is a difficult task for which many algorithms and methods have been proposed in the past decades. In this work, three deep learning methods, namely stacked autoencoder (SAE), generative adversarial networks (GANs) and U-Nets are investigated, evaluated and compared for 3D reconstruction from a 2D grayscale image of laser-welded components. In this work, different variants of GANs are tested, with the conclusion that Wasserstein GANs (WGANs) are the most robust approach among them. To the best of our knowledge, the present paper considers for the first time the U-Net, which achieves outstanding results in semantic segmentation, in the context of 3D reconstruction tasks. Unlike the U-Net, which uses standard convolutions, the stacked dilated U-Net (SDU-Net) applies stacked dilated convolutions. Of all the 3D reconstruction approaches considered in this work, the SDU-Net shows the best performance, not only in terms of evaluation metrics but also in terms of computation time. Due to the comparably small number of trainable parameters and the suitability of the architecture for strong data augmentation, a robust model can be generated with only a few training data

Observing Strategies for the NICI Campaign to Directly Image Extrasolar Planets

We discuss observing strategy for the Near Infrared Coronagraphic Imager (NICI) on the 8-m Gemini South telescope. NICI combines a number of techniques to attenuate starlight and suppress superspeckles: 1) coronagraphic imaging, 2) dual channel imaging for Spectral Differential Imaging (SDI) and 3) operation in a fixed Cassegrain rotator mode for Angular Differential Imaging (ADI). NICI will be used both in service mode and for a dedicated 50 night planet search campaign. While all of these techniques have been used individually in large planet-finding surveys, this is the first time ADI and SDI will be used with a coronagraph in a large survey. Thus, novel observing strategies are necessary to conduct a viable planet search campaign.Comment: 12 pages, 10 figures, submitted to Proceedings of the SPI

NICI: combining coronagraphy, ADI, and SDI

The Near-Infrared Coronagraphic Imager (NICI) is a high-contrast AO imager at the Gemini South telescope. The camera includes a coronagraphic mask and dual channel imaging for Spectral Differential Imaging (SDI). The instrument can also be used in a fixed Cassegrain Rotator mode for Angular Differential Imaging (ADI). While coronagraphy, SDI, and ADI have been applied before in direct imaging searches for exoplanets. NICI represents the first time that these 3 techniques can be combined. We present preliminary NICI commissioning data using these techniques and show that combining SDI and ADI results in significant gains.Comment: Proc. SPIE, Vol. 7014, 70141Z (2008

Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis.

BACKGROUND:Retinal optical coherence tomography (OCT) is a clinical and research tool in multiple sclerosis, where it has shown significant retinal nerve fiber (RNFL) and ganglion cell (RGC) layer thinning, while postmortem studies have reported RGC loss. Although retinal pathology in experimental autoimmune encephalomyelitis (EAE) has been described, comparative OCT studies among EAE models are scarce. Furthermore, the best practices for the implementation of OCT in the EAE lab, especially with afoveate animals like rodents, remain undefined. We aimed to describe the dynamics of retinal injury in different mouse EAE models and outline the optimal experimental conditions, scan protocols, and analysis methods, comparing these to histology to confirm the pathological underpinnings. METHODS:Using spectral-domain OCT, we analyzed the test-retest and the inter-rater reliability of volume, peripapillary, and combined horizontal and vertical line scans. We then monitored the thickness of the retinal layers in different EAE models: in wild-type (WT) C57Bl/6J mice immunized with myelin oligodendrocyte glycoprotein peptide (MOG35-55) or with bovine myelin basic protein (MBP), in TCR2D2 mice immunized with MOG35-55, and in SJL/J mice immunized with myelin proteolipid lipoprotein (PLP139-151). Strain-matched control mice were sham-immunized. RGC density was counted on retinal flatmounts at the end of each experiment. RESULTS:Volume scans centered on the optic disc showed the best reliability. Retinal changes during EAE were localized in the inner retinal layers (IRLs, the combination of the RNFL and the ganglion cell plus the inner plexiform layers). In WT, MOG35-55 EAE, progressive thinning of IRL started rapidly after EAE onset, with 1/3 of total loss occurring during the initial 2 months. IRL thinning was associated with the degree of RGC loss and the severity of EAE. Sham-immunized SJL/J mice showed progressive IRL atrophy, which was accentuated in PLP-immunized mice. MOG35-55-immunized TCR2D2 mice showed severe EAE and retinal thinning. MBP immunization led to very mild disease without significant retinopathy. CONCLUSIONS:Retinal neuroaxonal damage develops quickly during EAE. Changes in retinal thickness mirror neuronal loss and clinical severity. Monitoring of the IRL thickness after immunization against MOG35-55 in C57Bl/6J mice seems the most convenient model to study retinal neurodegeneration in EAE

The Gemini NICI Planet-Finding Campaign

Our team is carrying out a multi-year observing program to directly image and characterize young extrasolar planets using the Near-Infrared Coronagraphic Imager (NICI) on the Gemini-South 8.1-meter telescope. NICI is the first instrument on a large telescope designed from the outset for high-contrast imaging, comprising a high-performance curvature adaptive optics system with a simultaneous dual-channel coronagraphic imager. Combined with state-of-the-art observing methods and data processing, NICI typically achieves ~2 magnitudes better contrast compared to previous ground-based or space-based programs, at separations inside of ~2 arcsec. In preparation for the Campaign, we carried out efforts to identify previously unrecognized young stars, to rigorously construct our observing strategy, and to optimize the combination of angular and spectral differential imaging. The Planet-Finding Campaign is in its second year, with first-epoch imaging of 174 stars already obtained out of a total sample of 300 stars. We describe the Campaign's goals, design, implementation, performance, and preliminary results. The NICI Campaign represents the largest and most sensitive imaging survey to date for massive (~1 Mjup) planets around other stars. Upon completion, the Campaign will establish the best measurements to date on the properties of young gas-giant planets at ~5-10 AU separations. Finally, Campaign discoveries will be well-suited to long-term orbital monitoring and detailed spectrophotometric followup with next-generation planet-finding instruments.Comment: Proceedings of the SPIE, vol 7736 (Advances in Adaptive Optics, San Diego, CA, June 2010 meeting), in pres

Auf dem Weg zur individualisierten Medizin - Grid-basierte Services für die EPA der Zukunft.

Personalized Medicine is of paramount interest for many areas in Medical Informatics. Therefore genotype data as well a phenotype data about patients have to be available. This data will be stored in Electronic Health Records or – patient controlled - in Personal Health Records. As the amount of (raw) data is rising continuously, methods for a secure data administration have to be found. Grid Services offer data storage, can support data retrieval and the presentation of the data. The basic security services could be provided by the German health professional infrastructure, but there are many security challenges to be faced

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis

Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS). There is, however, concern that it may cause irreversible cardiomyopathy with reduced left ventricular (LV) ejection fraction (EF) and congestive heart failure. The aim of this prospective study was to investigate cardiac side effects of mitoxantrone by repetitive cardiac monitoring in MS patients. The treatment protocol called for ten courses of a combined mitoxantrone (10 mg/m(2) body surface) and methylprednisolone therapy. Before each course, a transthoracic echocardiogram was performed to determine the LV end-diastolic diameter, the end-systolic diameter and the fractional shortening; the LV-EF was calculated. Seventy-three patients participated (32 males; age 48 +/- 12 years, range 20-75 years; 25 with primary progressive, 47 with secondary progressive and 1 with relapsing-remitting MS) who received at least four courses of mitoxantrone. Three of the 73 patients were excluded during the study (2 patients discontinued therapy; 1 patient with a previous history of ischemic heart disease developed atrial fibrillation after the second course of mitoxantrone). The mean cumulative dose of mitoxantrone was 114.0 +/- 33.8 mg. The mean follow-up time was 23.4 months (range 10-57 months). So far, there has been no significant change in any of the determined parameters (end-diastolic diameter, end-systolic diameter, fractional shortening, EF) over time during all follow-up investigations. Mitoxantrone did not cause signs of congestive heart failure in any of the patients. Further cardiac monitoring is, however, needed to determine the safety of mitoxantrone after longer follow-up times and at higher cumulative doses. Copyright (C) 2005 S. Karger AG, Basel

CADDIE - An online knowledge base for network-based mechanism exploration and drug repurposing in oncolog

Drug repurposing is the use of previously developed and tested pharmaceutical agents in new application cases and lately often used as a solution to the increasing drug development costs. Cancers are extremely heterogeneous disorders demonstrating a wide variability of drug responses due to diverse subtypes, quickly evolving and acquiring drug resistance. Therefore, the identification of compounds that can effectively combat a specific tumor type is crucial. Drug candidates that are potentially effective against a specific tumor can be chosen based on the set of driver mutations acquired by this tumor. For optimal treatment, it is important to consider targeted anti-cancer therapies and drugs initially developed to treat non-cancerous diseases. To overcome this hurdle, we present CADDIE (Cancer Driver Drug Interaction Explorer), a web platform to identify oncological drug repurposing candidates. CADDIE’s biomedical knowledge base integrates a multitude of gene-gene and drug-gene interaction datasets, detailed anticancer drug information and cancer biology data such as cancer driver genes, mutation frequencies and gene expressions. For the purpose of locating drug targets and candidates for drug repurposing, CADDIE makes network medicine algorithms available to the researchers. It guides the users from the choice of seed genes through the discovery of therapeutic targets or drug candidates. Network medicine also provides indirect strategies that take into account other functionally relevant targets in the gene interaction network since potential cancer driver genes may be inaccessible for direct targeting. We demonstrate the application of CADDIE in different cancer subtypes such as sarcoma and ovarian cancer with a detailed analysis of the found drug targets and chemical compounds. CADDIE is available online at https://exbio.wzw.tum.de/caddie/ and as a python package at https://pypi.org/project/caddiepy/.Book of abstract: 4th Belgrade Bioinformatics Conference, June 19-23, 202

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

$\textbf{Objective:}$ To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. $\textbf{Methods:}$ Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-β-1a (SC IFN-β-1a) 44 μg in patients with RRMS. Prespecified and post hoc disability outcomes based on Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and Sloan low-contrast letter acuity (SLCLA) are reported, focusing on improvement of preexisting disability in addition to slowing of disability accumulation. $\textbf{Results:}$ Alemtuzumab-treated patients were more likely than SC IFN-β-1a-treated patients to show improvement in EDSS scores ($p$ < 0.0001) on all 7 functional systems. Significantly more alemtuzumab patients demonstrated 6-month confirmed disability improvement. The likelihood of improved vs stable/worsening MSFC scores was greater with alemtuzumab than SC IFN-β-1a ($p$ = 0.0300); improvement in MSFC scores with alemtuzumab was primarily driven by the upper limb coordination and dexterity domain. Alemtuzumab-treated patients had more favorable changes from baseline in SLCLA (2.5% contrast) scores ($p$ = 0.0014) and MSFC + SLCLA composite scores ($p$ = 0.0097) than SC IFN-β-1a-treated patients. $\textbf{Conclusions:}$ In patients with RRMS and inadequate response to prior disease-modifying therapies, alemtuzumab provides greater benefits than SC IFN-β-1a across several disability outcomes, reflecting improvement of preexisting disabilities. $\textbf{Classification of evidence:}$ This study provides Class I evidence (based on rater blinding and a balance in baseline characteristics between arms) that alemtuzumab modifies disability measures favorably compared with SC IFN-β-1a.Sanofi Genzyme, Bayer HealthCare Pharmaceutical